PMID- 34557039
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20220426
IS  - 1179-1322 (Print)
IS  - 1179-1322 (Electronic)
IS  - 1179-1322 (Linking)
VI  - 13
DP  - 2021
TI  - SOX10 Knockdown Inhibits Melanoma Cell Proliferation via Notch Signaling Pathway.
PG  - 7225-7234
LID - 10.2147/CMAR.S329331 [doi]
AB  - PURPOSE: Melanoma is a serious and malignant disease worldwide. Seeking 
      diagnostic markers and potential therapeutic targets is urgent for melanoma 
      treatment. SOX10, a member of the SoxE family of genes, is a transcription factor 
      which can regulate the transcription of a wide variety of genes in multiple 
      cellular processes. METHODS: The mRNA level and protein expression of SOX10 is 
      confirmed by bioinformatic analysis and IHC staining. MTT, clone formation and 
      EdU analysis showed that SOX10 knockdown (KD) could significantly inhibit 
      melanoma cell proliferation. FACS analysis showed that SOX10 KD could markedly 
      enhance the level of cell apoptosis. The downstream target signaling pathway is 
      predicted by RNA-seq based on the public GEO database. The activation of Notch 
      signaling mediated by SOX10 is tested by qPCR and Western blot. RESULTS: Ectopic 
      upregulation of SOX10 was found in melanoma patient tissues compared to normal 
      nevus tissues in mRNA and protein levels. Furthermore, both mRNA and protein 
      level of SOX10 were negatively correlated with melanoma patient's prognosis. 
      SOX10 knockdown could obviously suppress the proliferation ability of melanoma 
      cells by inactivating Notch signaling pathway. CONCLUSION: Our study confirmed 
      that SOX10 is an oncogene and activate Notch signaling pathway, which suggests 
      the potential treatment for melanoma patients by target SOX10/Notch axis.
CI  - (c) 2021 Tang and Cao.
FAU - Tang, Youqun
AU  - Tang Y
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha, 410013, Hunan, People's Republic of China.
FAU - Cao, Yanming
AU  - Cao Y
AD  - Department of Oncology, The Third Xiangya Hospital, Central South University, 
      Changsha, 410013, Hunan, People's Republic of China.
LA  - eng
PT  - Journal Article
DEP - 20210917
PL  - New Zealand
TA  - Cancer Manag Res
JT  - Cancer management and research
JID - 101512700
PMC - PMC8455513
OTO - NOTNLM
OT  - SOX10
OT  - bioinformatics
OT  - biomarkers
OT  - melanoma
OT  - proliferation
COIS- The authors report no conflicts of interest in this work.
EDAT- 2021/09/25 06:00
MHDA- 2021/09/25 06:01
PMCR- 2021/09/17
CRDT- 2021/09/24 07:04
PHST- 2021/07/14 00:00 [received]
PHST- 2021/08/19 00:00 [accepted]
PHST- 2021/09/24 07:04 [entrez]
PHST- 2021/09/25 06:00 [pubmed]
PHST- 2021/09/25 06:01 [medline]
PHST- 2021/09/17 00:00 [pmc-release]
AID - 329331 [pii]
AID - 10.2147/CMAR.S329331 [doi]
PST - epublish
SO  - Cancer Manag Res. 2021 Sep 17;13:7225-7234. doi: 10.2147/CMAR.S329331. 
      eCollection 2021.